S&P Global Inc. (SPGI) Forms $189.29 Double Top; Bio-Rad Laboratories, Inc. (BIO) Had 3 Bullish Analysts

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

Among 5 analysts covering Bio-Rad Laboratories (NYSE:BIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Bio-Rad Laboratories had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Buy” rating given on Thursday, October 13 by CL King. Wells Fargo maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) rating on Wednesday, November 29. Wells Fargo has “Buy” rating and $290.0 target. CL King downgraded the stock to “Neutral” rating in Friday, February 16 report. The rating was maintained by Wells Fargo with “Outperform” on Wednesday, February 28. The stock has “Buy” rating by Jefferies on Thursday, July 13. The rating was maintained by Jefferies on Friday, April 28 with “Buy”. Jefferies maintained the stock with “Buy” rating in Wednesday, April 12 report. The firm has “Buy” rating by Jefferies given on Wednesday, September 7. The firm has “Buy” rating by Jefferies given on Wednesday, September 27. Jefferies maintained it with “Buy” rating and $27500 target in Thursday, June 8 report. See Bio-Rad Laboratories, Inc. (NYSE:BIO) latest ratings:

20/03/2018 Broker: Wells Fargo Rating: Buy New Target: $290.0 Maintain
28/02/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $290 New Target: $280 Maintain
16/02/2018 Broker: CL King Old Rating: Buy New Rating: Neutral Downgrade
16/02/2018 Broker: C.L. King Rating: Hold Downgrade
29/11/2017 Broker: Wells Fargo Rating: Buy New Target: $290.0 Maintain
03/11/2017 Broker: Jefferies Rating: Buy New Target: $300.0 Maintain

S&P Global Inc. (SPGI) formed double top with $206.32 target or 9.00% above today’s $189.29 share price. S&P Global Inc. (SPGI) has $47.57B valuation. The stock decreased 0.39% or $0.745 during the last trading session, reaching $189.285. About 118,387 shares traded. S&P Global Inc. (NYSE:SPGI) has risen 46.26% since May 2, 2017 and is uptrending. It has outperformed by 34.71% the S&P500.

Since December 14, 2017, it had 0 insider purchases, and 1 insider sale for $1.24 million activity. TSINGOS CHRISTINE A sold $1.24M worth of stock or 4,980 shares.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.35, from 0.78 in 2017Q3. It increased, as 23 investors sold Bio-Rad Laboratories, Inc. shares while 89 reduced holdings. 44 funds opened positions while 82 raised stakes. 18.57 million shares or 0.31% more from 18.51 million shares in 2017Q3 were reported. Bluemountain Mngmt Limited, New York-based fund reported 10,791 shares. Moreover, Comerica Natl Bank has 0.03% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO). Alliancebernstein L P holds 0.06% or 325,946 shares. Qs Ltd has 1,007 shares. Fincl Bank Of America Corporation De has 0.01% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 330,418 shares. Ameriprise Fincl reported 65,743 shares or 0.01% of all its holdings. Stevens Capital L P has 5,860 shares for 0.05% of their portfolio. Art Ltd owns 1,800 shares. 4,324 are held by Virtu Fincl. Moreover, Swiss Bancorp has 0.01% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO). Hitchwood Capital L P stated it has 420,000 shares or 3.76% of all its holdings. Gsa Capital Limited Liability Partnership stated it has 0.06% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Tudor Invest Corp Et Al, Connecticut-based fund reported 2,580 shares. Castleark Management Limited Co owns 0.14% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 19,280 shares. Prelude Mgmt Llc, New York-based fund reported 7,222 shares.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $7.65 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 67.1 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

The stock increased 1.22% or $3.08 during the last trading session, reaching $256.33. About 12,689 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 25.02% since May 2, 2017 and is uptrending. It has outperformed by 13.47% the S&P500.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart